Can Wegovy Make You Diabetic? Correcting a Common Concern

The misconception: why people worry Wegovy could cause diabetes

A question our prescribers hear most weeks goes something like this: "I've read that Wegovy affects your pancreas, could it give me diabetes?" The short answer is no, but the worry isn't baseless. GLP-1 medicines work partly by stimulating the pancreas to release insulin, and that mechanism raises a reasonable question in people who are not medically trained. There is also a separate concern about pancreatitis (an inflammation of the pancreas) which is a known, infrequent side effect of GLP-1 receptor agonists. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as something to take seriously: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Pancreatitis and diabetes are different conditions. Causing pancreatitis does not mean causing diabetes, and if you want to understand in full whether semaglutide can make you diabetic, the clinical trial evidence shows no signal that it raises the risk of developing type 2 diabetes in people who did not already have it.

The confusion sometimes comes from conflating Wegovy with Ozempic. Both contain semaglutide, but Ozempic is licensed for treating type 2 diabetes, not for weight loss. Wegovy is the weight-management licence. People searching for information across both brands encounter a lot of diabetes content, which muddies the waters. Our Wegovy overview page sets out what the medicine is licensed for in the UK and how the two products differ.

What semaglutide actually does to blood sugar

Semaglutide is a GLP-1 receptor agonist. In practical terms, it mimics a gut hormone that tells the body to release insulin after eating, slows how quickly food leaves the stomach, and reduces appetite signals in the brain. Crucially, the insulin-stimulating effect is glucose-dependent: the medicine only prompts more insulin when blood sugar is actually rising. At normal or low glucose levels, it does not push insulin release further. That is why hypoglycaemia (abnormally low blood sugar) is rarely caused by semaglutide on its own in people who do not already take insulin or sulfonylurea medicines.

For people without diabetes, this mechanism does not disrupt glucose regulation, it works within it. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity but without diabetes for 68 weeks; participants lost an average of around 15% of their body weight on semaglutide 2.4mg, with no evidence that the medicine caused new-onset diabetes. Weight loss itself can meaningfully improve insulin sensitivity, so treatment may actually move some people away from prediabetes rather than towards it.

If you already have type 2 diabetes and are wondering whether Wegovy is an option for you, our guidance on whether diabetics can use Wegovy covers the specific considerations in detail.

Who needs to take particular care and when to speak to a clinician

Certain groups need a careful clinical conversation before starting or continuing semaglutide, regardless of diabetes risk. Anyone with a history of pancreatitis should discuss this with their prescriber, as should people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. These are contraindications set out in the prescribing guidance, not theoretical cautions.

If you notice unusual thirst, needing to urinate far more often than usual, unexpected fatigue, or blurred vision during treatment, tell a healthcare professional. These could point to blood-sugar changes that warrant investigation. Do not adjust your dose or stop your medicine before getting that advice. You can also report unexpected symptoms through the MHRA Yellow Card scheme, which exists precisely to capture real-world patterns in people using medicines.

For people with type 2 diabetes who want to understand the overlap between their diabetes medicines and weight-loss treatment, our clinical team reviews each case individually. The page on Wegovy for people with type 2 diabetes is a good starting point, and you can always raise specific questions through our support team, who are available seven days a week.

Pregnancy, breastfeeding, and trying to conceive are clear situations where semaglutide is not recommended. If any of those apply to you, stop treatment and speak to your GP promptly. Our page on Wegovy and pregnancy covers what is known and what to do next.